What is Zacks Research’s Forecast for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research raised their Q1 2026 earnings per share estimates for shares of Omnicell in a research report issued on Thursday, February 26th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.13 per share for the quarter, up from their prior estimate of $0.09. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s FY2026 earnings at $0.87 EPS, Q1 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.29 EPS, FY2027 earnings at $1.11 EPS and FY2028 earnings at $1.40 EPS.

Other equities analysts have also issued research reports about the stock. Benchmark upped their target price on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings upgraded shares of Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, February 9th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price on the stock in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company raised their target price on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Omnicell Price Performance

Shares of Omnicell stock opened at $41.10 on Monday. The stock’s 50-day simple moving average is $45.05 and its 200-day simple moving average is $38.01. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 1,027.76, a PEG ratio of 1.47 and a beta of 0.79. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. Omnicell’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.52% of the stock is owned by insiders.

Institutional Trading of Omnicell

Several large investors have recently bought and sold shares of OMCL. Dimensional Fund Advisors LP grew its holdings in shares of Omnicell by 9.1% during the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after buying an additional 197,462 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after acquiring an additional 1,265,818 shares during the period. Lazard Asset Management LLC increased its holdings in Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after purchasing an additional 30,678 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Omnicell in the third quarter valued at approximately $25,625,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.